Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small-cell lung cancer.
Myrto K MoutafiMagdalena MoleroSandra Martinez MorillaJavier BaenaIoannis A VathiotisNiki GavrielatouLaura Castro-LabradorGorka Ruiz de GaribayVera AdradasDaniel OriveKarmele ValenciaAlfonso CalvoLuis M MontuengaS Ponce AixKurt A SchalperRoy S HerbstLuis Paz-AresDavid L RimmJon ZugazagoitiaPublished in: Journal for immunotherapy of cancer (2022)
This work highlights CD44 as a novel indicative biomarker of sensitivity to PD-1 axis blockade that might help to improve immunotherapy strategies for NSCLC.